Page 86 - DUOKOPT BIBLIOBOOK

DUOKOPT - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

IOP-Lowering Effects of Fixed-Combination Drugs

Quality score 18 14 17 14 18 16 15 17 13 16 16 18 17 18 18 18 18 13 18

IOP* ] (SD)
Baseline Hg) (mm [mean (5.0) 27.8 (3.7) 25.4 (0.9) 24.9 (1.4) 25.8 - (3.7) 28.4 (3.6) 25.0 (2.6) 27.4 (2.5) 24.7 (3.2) 26.9 (2.4) 25.9 (2.7) 30.2 (2.8) 26.5 (2.7) 25.6 (2.3) 25.3 (2.3) 26.0 (3.3) 26.7 (3.2) 22.0 (2.7) 24.7

or (%)
POAG OHT 100 97 100 100 99 98 92 96 100 97 100 100 100 97 97 91 90 100 100

Sex (M/F) 54/60 9/20 9/11 15/18 125/148 112/139 47/70 73/90 9/13 12/23 9/23 37/45 14/23 63/92 57/94 129/126 46/45 - 181/204
age
Mean (years) 62.4 62.7 63.0 64.8 62.8 63.5 61.1 65.5 63.5 64.5 61.5 63.0 65.8 62.0 64.2 65.0 63.9 59.2 62.0

Withdrawals (%) 0.3 0.0 0.0 2.9 8.8 4.3 6.0 6.0 0.0 8.6 8.6 3.9 0.0 7.7 7.5 11.0 8.8 0.0 25.7

Total no. 114 29 20 33 273 251 117 163 22 35 32 82 37 155 151 255 91 14 385

Duration Months 3 Months 3 Month 1 Weeks 6 Months 3 Months 3 Weeks 8 Months 6 Months 3 Weeks 6 Weeks 8 Months 3 Weeks 8 Months 3 Months 3 Weeks 12 Weeks 6 Month 1 Months 12

Route AM, 8:30 PM 8:30 AM, 8 PM 8 AM, 8 PM 8 AM, 8 PM 8 AM, 8 PM 10 AM 8 AM, 8 PM 8 AM, 8 PM 8 AM 8 AM 9 AM 8 AM, 8 PM 8 AM 8 PM 8 AM 8 AM 8 PM 8 AM 9 PM 9 AM 7 AM, 8 PM 8

trials. 0.004% timolol

clinical Intervention Medication Dorzolamide/ timolol Dorzolamide/ timolol Dorzolamide/ timolol Dorzolamide/ timolol Dorzolamide/ timolol Latanoprost/ 2.0% timolol Dorzolamide/ timolol Dorzolamide/0.5% Latanoprost/ timolol Latanoprost/ timolol Latanoprost/ timolol Dorzolamide/ timolol Travoprost/ timolol Latanoprost/ timolol Travoprost/ timolol Travoprost/ timolol Latanoprost/ timolol Travoprost/ timolol Travoprost/0.5

randomized 2.0% 0.5% 2.0% 0.5% 2.0% 0.5% 2.0% 0.5% 2.0% 0.5% 0.005% 0.5% 0.5% 2.0% timolol 0.005% 0.5% 0.005% 0.5% 0.005% 0.5% 2.0% 0.5% 0.004% 0.5% 0.005% 0.5% 0.004% 0.5% 0.004% 0.5% 0.005% 0.5% 0.004% 0.5% 0.005% 0.5% 0.2% timolol

eligible Centre 27 8 1 2 44 30 13 34 1 3 3 33 1 27 19 53 Multi 1 53

of Location Europe, America
characteristics U.S. PG U.S. PG Italy CR Greece U.S., PG Israel U.S. Latin PG Europe Spain U.S. CR U.S. CR U.S. PG Greece U.S. PG U.S. PG Europe, PG Canada France PG Brazil U.S. PG

Baseline Design DB, DB, DB, CR SB, DB, PG SB, OL, PG SB, PG SB, DB, DB, DB, CR SB, DB, DB, DB, DB, PG SB, DB,

2. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27]
Table Trial 199810/01 200303/01 200304/01 200307/01 200402/01 200402/02 200405/01 200407/01 200409/01 200410/01 200505/01 200507/01 200507/02 200508/01 200510/01 200601/01 200603/01 200603/02 200609/01

PLOS ONE | www.plosone.org 4 September 2012 | Volume 7 | Issue 9 | e45079
86